Close
Back to CALA Stock Lookup
Pages: 1 2 3 4 »» Last Page

Calithera Biosciences (CALA) – StreetInsider.com Reports

Jun 29, 2023 04:01 PM Calithera Biosciences (CALA) Issues Update on Complete Liquidation and Dissolution
May 19, 2023 04:01 PM Calithera Biosciences (CALA) Announces Update on Complete Liquidation and Dissolution
Jan 9, 2023 04:36 PM U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.34%
Jan 9, 2023 08:02 AM Calithera Biosciences (CALA) Announces Board Approval of Complete Liquidation and Dissolution
Jan 9, 2023 07:55 AM Calithera Biosciences (CALA) Halted, News Pending
Nov 15, 2022 07:01 AM UPDATE: Ladenburg Thalmann Downgrades Calithera Biosciences (CALA) to Neutral
Nov 15, 2022 05:00 AM UPDATE: SVB Leerink Downgrades Calithera Biosciences (CALA) to Market Perform
Nov 14, 2022 04:19 PM Calithera Biosciences (CALA) Reports Q3 Net Loss of $9.8M
Oct 3, 2022 07:08 AM Calithera Biosciences (CALA) Receives FDA Fast Track Designation for Sapanisertib for the Treatment of NRF2-mutated Squamous Lung Cancer
Aug 29, 2022 06:26 AM UPDATE: H.C. Wainwright Upgrades Calithera Biosciences (CALA) to Buy
Aug 15, 2022 04:18 PM Calithera Biosciences (CALA) Reports Q2 Net Loss of $9.1M
Jul 13, 2022 04:01 PM Calithera Biosciences (CALA) Shares Progress in Sapanisertib and Mivavotinib Clinical Programs at Upcoming Lung Cancer and Lymphoma Conferences
Jul 13, 2022 12:07 PM Calithera Biosciences (CALA) granted Australian patent number 2020286278 - Patent Grants
Jun 14, 2022 12:51 PM Calithera Biosciences (CALA) Announces 1-for-20 Reverse Stock Split
May 11, 2022 06:54 AM Calithera Biosciences (CALA) PT Lowered to $2 at Wells Fargo
May 11, 2022 06:48 AM Calithera Biosciences (CALA) PT Lowered to $1.50 at Ladenburg Thalmann
Apr 1, 2022 06:41 AM Calithera Biosciences (CALA) PT Lowered to $3 at Ladenburg Thalmann
Mar 30, 2022 05:56 AM Calithera Biosciences (CALA) Prices 18.5M Share Offering at $0.54/sh
Mar 29, 2022 04:01 PM Calithera Biosciences (CALA) Commences Stock and Warrant Offering
Jan 31, 2022 06:38 AM Ladenburg Thalmann Starts Calithera Biosciences (CALA) at Buy
Jan 20, 2022 09:29 AM Pre-Open Stock Movers 01/20: (CALA) (CRSP) (HCWB) Higher; (AMH) (DFS) (F) Lower (more...)
Jan 20, 2022 09:21 AM UPDATE: SVB Leerink Upgrades Calithera Biosciences (CALA) to Outperform
Dec 17, 2021 02:06 PM Calithera Biosciences (CALA) granted European patent number EP3538111 titled "ARGINASE INHIBITOR COMBINATION THERAPIES" - PatentGrants
Nov 8, 2021 06:22 AM H.C. Wainwright Downgrades Calithera Biosciences (CALA) to Neutral
Nov 5, 2021 10:39 AM William Blair Downgrades Calithera Biosciences (CALA) to Market Perform, Following Clinical Business Update
Nov 5, 2021 07:02 AM Calithera Biosciences (CALA) Appoints Emil T. Kuriakose as Chief Medical Officer
Nov 1, 2021 07:02 AM Calithera Biosciences (CALA) Reports Promising Interim Data from Phase 1b Trial of Arginase Inhibitor CB-280 in Cystic Fibrosis
Oct 18, 2021 04:08 PM Calithera Biosciences (CALA) Acquires Two Clinical-Stage Assets from Takeda Pharmaceuticals
May 17, 2021 09:25 AM Pre-Open Stock Movers 05/17: (EJH) (APLS) (DISCA) Higher; (MARA) (RIOT) (MSTR) Lower (more...)
May 17, 2021 08:21 AM Antengene and Calithera Biosciences (CALA) Enter into Worldwide Exclusive License Agreement to Develop and Commercialize CD73 Inhibitor CB-708
May 17, 2021 08:12 AM Calithera Biosciences (CALA) and Antengene Enter Worldwide License Agreement for Development & Commercialization of CB-708
Jan 5, 2021 06:42 AM Calithera Biosciences (CALA) PT Lowered to $4 at H.C. Wainwright
Jan 5, 2021 05:56 AM Calithera Biosciences (CALA) PT Lowered to $5 at Citi
Jan 4, 2021 04:43 PM SVB Leerink Downgrades Calithera Biosciences (CALA) to Market Perform
Jan 4, 2021 10:17 AM Increasing unusual option volume: CALA QS FOLD PSTG AEO OEG LC
Jan 4, 2021 09:28 AM Pre-Open Stock Movers 01/04: (OCGN) (BNGO) (FLIR) Higher; (CALA) (GNW) (QS) Lower (more...)
Jan 4, 2021 07:05 AM Calithera Biosciences (CALA) CANTATA Study of Telaglenastat in Renal Cell Carcinoma Did Not Achieve Primary Endpoint
Nov 4, 2020 01:07 PM Calithera Biosciences (CALA) Reports Expansion of Ongoing Clinical Trial Evaluating Telaglenastat in Combination with Palbociclib (IBRANCE)
Sep 24, 2020 07:12 AM Calithera Biosciences (CALA) Begins KEAPSAKE Randomized Phase 2 Trial of Telaglenastat in Combination with Chemoimmunotherapy to Treat Aggressive Form of Lung Cancer
Aug 11, 2020 05:16 AM Calithera Biosciences (CALA) PT Lowered to $7 at SVB Leerink
Jul 14, 2020 07:06 AM Calithera Biosciences (CALA) Names Scott Garland to Board
May 11, 2020 05:22 AM Calithera Biosciences (CALA) PT Raised to $10 at Citi
Apr 16, 2020 09:19 AM Pre-Open Stock Movers 04/16: (RCUS) (LOVE) (BBBY) Higher; (DO) (RAD) (ATHX) Lower (more...)
Apr 16, 2020 05:52 AM Calithera Biosciences (CALA) Prices 5M Share Common Offering at $6.25/Sh
Apr 15, 2020 06:03 PM After-Hours Stock Movers 04/15: (RCUS) (AM) (BBBY) Higher; (ATHX) (CALA) (LAKE) Lower (more...)
Apr 15, 2020 04:02 PM Calithera Biosciences (CALA) Commences Underwritten Public Offering of Common
Apr 14, 2020 07:05 AM Calithera Biosciences (CALA) Provides Update on Business Operations
Mar 27, 2020 05:24 AM Calithera Biosciences (CALA) PT Lowered to $7 at Citi
Mar 27, 2020 04:50 AM UPDATE: Jefferies Starts Calithera Biosciences (CALA) at Buy
Dec 6, 2019 07:07 AM Calithera Biosciences (CALA) Announces Data from Investigator-Sponsored Phase 2 Study of Calithera’s Telaglenastat with Azacitidine in Myelodysplastic Syndrome to be Presented at ASH
Pages: 1 2 3 4 »» Last Page

Back to CALA Stock Lookup